Veristat Joins the Alliance for Regenerative Medicine (ARM) to Help Address Critical Issues Impacting the Advanced Therapy Sector
The announcement falls the week before members of Veristat’s Executive team are attending ARM’s Cell & Gene Meeting on the Med (#MeetingOnTheMed) being held in Rome, Italy.
- The announcement falls the week before members of Veristat’s Executive team are attending ARM’s Cell & Gene Meeting on the Med (#MeetingOnTheMed) being held in Rome, Italy.
- “Advanced therapies have proven themselves as holding numerous benefits for patients struggling with rare and ultra-rare diseases, areas that account for 35% of our work,” stated Patrick Flanagan, Chief Executive Officer of Veristat.
- “Veristat is proud to have supported the development of the first gene therapy approved in Europe.
- ARM’s mission centers on enabling the development of advanced therapies and the modernization of healthcare systems so that patients benefit from durable, potentially curative treatments.